Masking and manipulation

Handbook of Experimental Pharmacology

Volumn 195, Issue , 2010, Pages 327-354

  Segura, Jordi ^a   Ventura, Rosa ^b  

^a HOSPITAL DEL MAR   (Spain)

^b NONE

Author keywords

5 Reductase inhibitors; Diuretics; Doping control; Epitestosterone; Masking gents; Plasma expanders; Probenecid

Indexed keywords

ACETAZOLAMIDE; AMILORIDE; ANDROGEN; BENDROFLUMETHIAZIDE; BENZTHIAZIDE; BUMETANIDE; CANRENONE; CARBONATE DEHYDRATASE INHIBITOR; CHLORTALIDONE; DICLOFENAMIDE; DIURETIC AGENT; EPITESTOSTERONE; ERYTHROPOIETIN; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; PIRETANIDE; PLASMA SUBSTITUTE; PROBENECID; SPIRONOLACTONE; TESTOSTERONE; TRIAMTERENE; STEROID 5ALPHA REDUCTASE; URICOSURIC AGENT;

DOPING; DRUG MECHANISM; DRUG MISUSE; DRUG STRUCTURE; ERYTHROCYTE CONCENTRATE; MASKING; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; URINE PH; URINE VOLUME; WEIGHT REDUCTION; DRUG ANTAGONISM; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY;

CHROMATOGRAPHY, LIQUID; DIURETICS; DOPING IN SPORTS; EPITESTOSTERONE; HUMANS; MASS SPECTROMETRY; PLASMA SUBSTITUTES; PROBENECID; TESTOSTERONE 5-ALPHA-REDUCTASE; URICOSURIC AGENTS;

EID: 77449141189     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79088-4_15     Document Type: Review

References (155)

1. Abshagen U et al (1976) Pharmacokinetics of spironolactone in man. Naunyn Schmiedebergs Arch Pharmacol 296:37-45
2. Adams HA et al (1998) Volume replacement solutions - pharmacology and clinical use. Anasthesiol Intensivmed Notfallmed Schmerzther 33:2-17
3. Aguilera R et al (2002) Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem 48:629-636
4. Amendola L et al (2003) Rapid determination of diuretics in human urinbe by gas chromatography-mass spectrometry following microwave assisted derivatization. Anal Chim Acta 475:125-136
5. Andreasen F et al (1981) The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol (Copenh) 49:223-229
6. Andriole G et al (2004) Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172:1399-1403
7. Armstrong LE et al (1985) Influence of diuretic-induced dehydration on competitive running performance. Med Sci Sports Exerc 17:456-461
8. Avois L et al (2004) Rapid screening of HES in urine with colorimetric detection. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (12). SportVerlag Strauss, Köln, pp 371-376
9. Barroso MB et al (1997) Gas chromatographic-mass spectrometric analysis of the loop diuretic torasemide in human urine. J Chromatogr B Biomed Sci Appl 690:105-113
10. Beermann B, Groschinsky-Grind M (1977) Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12:297-303
11. Beermann B et al (1976) Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther 19:531-537
12. Beermann B et al (1977) Pharmacokinetics of bendroflumethiazide. Clin Pharmacol Ther 22:385-388
13. Bellemare V et al (2005) Characterization of 17alpha-hydroxysteroid dehydrogenase activity (17alpha-HSD) and its involvement in the biosynthesis of epitestosterone. BMC Biochem 6:12
14. Beyer J et al (2005) Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. Ther Drug Monit 27:509-520
15. Bhardwa J et al (2007) Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 8:1337-1344
16. Boles Ponto LL, Schoenwald RD (1990) Furosemide: a pharmacokinetic/ pharmacodynamic review (part I). Clin Pharmacokinet 18:381-408
17. Brater DC et al (1983a) Effects of piretanide in normal subjects. Clin Pharmacol Ther 34:324-330
18. Brater DC et al (1983b) Bumetanide and furosemide. Clin Pharmacol Ther 34:207-213
19. Brooks RV, Giuliani G (1964) Epitestosterone:isolation from human urine and experiments on possible precursors. Steroids 4:101-116
20. Brunelli C et al (2006) High-speed gas chromatography in doping control:fast-GC and fast-GC/MS determination of beta-adrenoceptor ligands and diuretics. J Sep Sci 29:2765-2771
21. Burke A et al (2005) Analgesic-antipyretic agents; pharmacotherapy of gout. Goodman & Gilman's The pharmacological basis of therapeutics. McGraw-Hill, Medical Publishing Division, New York, pp 671-715
22. Caldwell JE (1987) Diuretic therapy and exercise performance. Sports Med 4:290-304
23. Caldwell JE et al (1984a) Differential effects of sauna-, diuretic-, and exercise-induced hypohydration. J Appl Physiol 57:1018-1023
24. Caldwell JE et al (1984b) Diuretic therapy, physical performance, and neuromuscular function. Physician Sportsmed 12:73-85
25. Camṕins P et al (1991) Solid-phaseextraction techniques for assay of diuretics in human urine samples. J Liq Chromatogr 14:3575-3590
26. Camṕins P et al (1993) Improved detection limits for screening of diuretics by coupled liquid chromatography and ultraviolet-visible spectrophotometry. J Chromatogr B Biomed Appl 612:245-251
27. Campins and Falcó (1994) Column-switching techniques for screening of diuretics and probenecid in urine samples. Anal Chem 66:244-248
28. Canguven O, Burnett AL (2008) The Effect of 5 {alpha}-reductase inhibitors on erectile function. J Androl 29(5):514-523
29. Carlin JR et al (1992) Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos 20:148-155
30. Carreras D et al (1994) Comparison of derivatization procedures for the determination of diuretics in urine by gas chromatography-mass spectrometry. J Chromatogr A 683:195-202
31. Catlin DH et al (2002) Effects of androstenedione administration on epitestosterone metabolism in men. Steroids 67:559-564
32. Cawley AT et al (2004) Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box". Forensic Sci Int 143:103-114
33. Chaffman M et al (1984) Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 28:189-235
34. Chapron DJ et al (1985) Influence of advanced age on the disposition of acetazolamide. Br J Clin Pharmacol 19:363-371
35. Clissold SP, Brogden RN (1985) Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 29:489-530
36. Cooper SF et al (1989) Comprehensive screening procedure for diuretics in urine by high-performance liquid chromatography. J Chromatogr 489:65-88
37. Cowan DA et al (2008) Ion trap MS/MS of intact testosterone and epitestosterone conjugates - adducts, fragile ions and the advantages of derivatisation. Steroids 73:621-628
38. Cunningham RF et al (1981) Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6:135-151
39. Cutler RE, Blair AD (1979) Clinical pharmacokinetics of frusemide. Clin Pharmacokinet 4:279-296
40. De Croo F et al (1985) High-performance liquid chromatographic behaviour of some pharmaceutically important thiazide, loop and potassium-sparing diuretics. J Chromatogr 325:395-411
41. de la Torre X et al (1997) Testosterone detection in different ethnic groups. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (4). Sport & Buch Strauss, Köln
42. Dehennin L (1993) Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3 beta, 17 alpha-diol. J Steroid Biochem Mol Biol 44:171-177
43. Delbeke FT, Debackere M (1985) The influence of diuretics on the excretion and metabolism of doping agents - I. Mephentermine. J Pharm Biomed Anal 3:141-148
44. Delbeke FT, Debackere M (1986a) The influence of diuretics on the excretion and metabolism of doping agents. II. Phentermine. Arzneimittelforschung 36:134-137
45. Delbeke FT, Debackere M (1986b) The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine. Arzneimittelforschung 36:1413-1416
46. Delbeke FT, Debackere M (1988) The influence of diuretics on the excretion and metabolism of doping agents. Part IV - Caffeine. Biopharm Drug Dispos 9:137-145
47. Delbeke FT, Debackere M (1991a) The influence of diuretics on the excretion and metabolism of doping agents - V. Dimefline. J Pharm Biomed Anal 9:23-28
48. Delbeke FT, Debackere M (1991b) The influence of diuretics on the excretion and metabolism of doping agents: Part VI. Pseudoephedrine. Biopharm Drug Dispos 12:37-48
49. Deventer K et al (2002) Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 16:529-535
50. Deventer K et al (2005) Simultaneous determination of beta-blocking agents and diuretics in doping analysis by liquid chromatography/mass spectrometry with scan-to-scan polarity switching. Rapid Commun Mass Spectrom 19:90-98
51. Deventer K et al (2006) Improved clean-up for the detection of hydroxyethylstarch (HES). In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (14). SportVerlag Strauss, Köln, pp 71-78
52. Dirks JH and Sutton RAL (1986) Diuretics. Physiology, pharmacology and clinical use, Elsevier Health Sciences (1), pp 396
53. Donike M et al (1984) Routinebestimmung von Anabolika in Harn. Dstch Z Sportmedizin 35:14-24
54. Donike M et al (1995) Detection of dihydrotestosterone (DHT) doping: alterations in the steroid profile and reference ranges for DHT and its 5 alpha-metabolites. J Sports Med Phys Fitness 35:235-250
55. Ehrhardt JD (1992) Negative-ion mass spectra of methylated diuretics. Rapid Commun Mass Spectrom 6:349-351
56. Falk O et al (1988) Effect of ethanol on the ratio between testosterone and epitestosterone in urine. Clin Chem 34:1462-1464
57. Feit PW et al (1973) GLC determination and urinary recovery of bumetanide in healthy volunteers. J Pharm Sci 62:375-379
58. Fleuren HL et al (1979a) Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration. Eur J Clin Pharmacol 15:35-50
59. Fleuren HL et al (1979b) Differential potentiometric method for determining dissociation constants of very slightly water-soluble drugs applied to the sulfonamide diuretic chlorthalidone. J Pharm Sci 68:1056-1058
60. Garbis SD et al (1998) Detection of thiazide-based diuretics in equine urine by liquid chromatography/mass spectrometry. J AOAC Int 81:948-957
61. Geyer H et al (1993) Probenecid as masking agent in doping - inhibition of the urinary excretion of steroid glucuronides. In: Proceedings 10th cologne workshop on dope analysis. Sport und Buch Strauss, Editio Sport, Köln, pp 141-150
62. Geyer H et al (1999) Finasteride - a substance for manipulation in dope control? In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (7). Sport & Buch StrauB, Köln, pp 71-80
63. Geyer H et al (2004) Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int J Sports Med 25:124-129
64. Gilfrich HJ et al (1983) Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol 25:237-241
65. Goebel C et al (2004) Rapid screening method for diuretics in doping control using automated solid phase extraction and liquid-chromatography- electrospray tandem mass spectrometry. Anal Chim Acta 502:65-74
66. Gonzalo-Lumbreras R et al (2003) Development and method validation for testosterone and epitestosterone in human urine samples by liquid chromatography applications. J Chromatogr Sci 41:261-265
67. Guddat S et al (2004) Detection and quantification of the plasma volume expander dextran in human urine. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (14). SportVerlag Strauss, Köln, pp 197-202
68. Guddat S et al (2005) Identification and quantification of the plasma volume expander dextran in human urine by liquid chromatography-tandem mass spectrometry of enzymatically derived isomaltose. Biomed Chromatogr 19:743-750
69. Gundert-Remy U et al (1979) Plasma and urinary levels of triamterene and certain metabolites after oral administration to man. Eur J Clin Pharmacol 16:39-44
70. Gutiérrez Gallego R, Segura J (2004) Rapid screening of plasma volume expanders in urine using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 18:1324-1330
71. Gutierrez Gallego R et al (2005) A microtiter assay to detect the presence of glucose-based plasma volume expanders in urine. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (13). SportVerlag Strauss, Köln, pp 383-386
72. Hagedorn HW, Schulz R (1992) Detection of diuretics in horse urine by GC/MS. J Anal Toxicol 16:194-198
73. Halladay SC et al (1977) Diuretic effect and metabolism of bumetanide in man. Clin Pharmacol Ther 22:179-187
74. Hasegawa J et al (1982) Pharmacokinetics of triamterene and its metabolite in man. J Pharmacokinet Biopharm 10:507-523
75. He C et al (2005) Extraction of testosterone and epitestosterone in human urine using aqueous two-phase systems of ionic liquid and salt. J Chromatogr A 1082:143-149
76. Henning UGG et al (1981a) Benzothiadiazine dissociation constants. Part I. Ultraviolet spectrophotometric pKa determinations. Analyst 106:557-564
77. Henning UGG et al (1981b) Benzothiadiazine dissociation constants. Part II. The order of deprotonation. Analyst 106:565-573
78. Hepner W et al (1984) A radioimmunoassay to measure piretanide in human serum and urine. J Immunoassay 5:13-27
79. Holazo AA et al (1984) Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J Pharm Sci 73:1108-1113
80. Hudak SJ et al (2006) Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin Interv Aging 1:425-431
81. Jackson E (2005) Diuretics. Goodman & Gilman's The pharmacological basis of therapeutics. McGraw-Hill, Medical Publishing Division, New York, pp 737-769
82. Jimenez C et al (2004) Reference materials for analytical toxicology including doping control: freeze-dried urine samples. Analyst 129:449-455
83. Jimenez C et al (2006) Stability studies of testosterone and epitestosterone glucuronides in urine. Rapid Commun Mass Spectrom 20:858-864
84. Jungheinrich C, Neff TA (2005) Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 44:681-699
85. Jungheinrich C et al (2002) The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 95:544-551; table
86. Karila T et al (1996) High doses of alcohol increase urinary testosterone-to-epitestosterone ratio in females. J Chromatogr B Biomed Appl 687:109-116
87. Karim A et al (1976a) Spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther 19:158-169
88. Karim A et al (1976b) Spironolactone. II. Bioavailability. Clin Pharmacol Ther 19:170-176
89. Kicman AT et al (1995) Proposed confirmatory procedure for detecting 5 alpha-dihydrotestoster-one doping in male athletes. Clin Chem 41:1617-1627
90. Kicman AT et al (1999) Adrenal and gonadal contributions to urinary excretion and plasma concentration of epitestosterone in men-effect of adrenal stimulation and implications for detection of testosterone abuse. Clin Endocrinol (Oxf) 50:661-668
91. Kolmonen M et al (2007) A general screening method for doping agents in human urine by solid phase extraction and liquid chromatography/time-of-flight mass spectrometry. Anal Chim Acta 585:94-102
92. Kuuranne T (2009) Phase-II-metabolism of androgens and its relevancy for doping control analysis. Handbook of Experimental Pharmacology (in press)
93. Lant A (1985a) Diuretics. Clinical pharmacology and therapeutic use (Part I). Drugs 29:57-87
94. Lant A (1985b) Diuretics. Clinical pharmacology and therapeutic use (Part II). Drugs 29:162-188
95. Lisi AM et al (1991) Screening for diuretics in human urine by gas chromatography-mass spectrometry with derivatisation by direct extractive alkylation. J Chromatogr 563:257-270
96. Lisi AM et al (1992) Diuretic screening in human urine by gas chromatography-mass spectrometry: use of a macroreticular acrylic copolymer for the efficient removal of the coextracted phase-transfer reagent after derivatization by direct extractive alkylation. J Chromatogr 581:57-63
97. Lu M et al (2007) A new method for screening and determination of diuretics by on-line CE-ESI-MS. Electrophoresis 28:1461-1471
98. Maren TH (1956) Carbonic anhydrase inhibition.V.N5-substituted 2-acetylamino-1,3,4-thiadiazole-5-sulfonamides: metabolic conversion and use as control substances. J Pharmacol Exp Ther 117:385-401
99. Marques MAS et al (1999) Effect of finasteride on urinary steroid profile: a case study. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (7). Sport and Buch Strauss, Köln, pp 317-322
100. Mazzarino M and Botre F (2008) Fast screening for the detection of HES and dextran. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (16). Sport und Buch Strauss, Köln, pp 329-332
101. Mehvar R (2000) Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release 69:1-25
102. Melethil S, Conway WD (1976) Urinary excretion of probenecid and its metabolites in humans as a function of dose. J Pharm Sci 65:861-865
103. Mishler JM et al (1981) Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man. J Clin Pathol 34:361-365
104. Moffat AC et al (2004) Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material, 3rd edn. Pharmaceutical Press, Paris
105. Morra V et al (2006) Fast gas chromatographic/mass spectrometric determination of diuretics and masking agents in human urine: Development and validation of a productive screening protocol for antidoping analysis. J Chromatogr A 1135:219-229
106. Orita Y et al (1976) A metal complexing property of furosemide and bumetanide: determination of pK and stability constant. Arzneimittelforschung 26:11-13
107. Park SJ et al (1990) Systematic analysis of diuretic doping agents by HPLC screening and GC/MS confirmation. J Anal Toxicol 14:84-90
108. Patel RB et al (1984) Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 73:359-361
109. Politi L et al (2007) A direct screening procedure for diuretics in human urine by liquid chromatography-tandem mass spectrometry with information dependent acquisition. Clin Chim Acta 386:46-52
110. Pozo OJ et al (2008) Direct quantification of steroid glucuronides in human urine by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A 1183:108-118
111. Ramakrishna NV et al (2004) Selective and rapid liquid chromatography-tandem mass spectrometry assay of dutasteride in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 809:117-124
112. Raynaud E et al (1993) Study of urinary excretion of testosterone and epitestosterone glucuronides in children and adolescents. Pathol Biol (Paris) 41:159-163
113. Riess W et al (1977) Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol 12:375-382
114. Roberts JS, Bratton SL (1998) Colloid volume expanders. Problems, pitfalls and possibilities. Drugs 55:621-630
115. Sabanathan K et al (1987) A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Clin Pharmacol 32:53-60
116. Salado S, Vera-Avila LE (1997) On-line solid-phase extraction and high-performance liquid chromatographic determination of chlorthalidone in urine. J Chromatogr B Biomed Sci Appl 690:195-202
117. Sander O et al (2003) Equivalence of hydroxyethyl starch HES 130/0. 4 and HES 200/0. 5 for perioperative volume replacement in major gynaecological surgery. Acta Anaesthesiol Scand 47:1151-1158
118. Sanz-Nebot V et al (2001) Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry. J Mass Spectrom 36:652-657
119. Saudan C et al (2006) Short-term stability of testosterone and epitestosterone conjugates in urine samples: quantification by liquid chromatography-linear ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 844:168-174
120. Saudan C et al (2008) Short term impact of Tribulus terrestris intake on doping control analysis of endogenous steroids. Forensic Sci Int 178(1):e7-e10
121. Schulze JJ et al (2008) Doping test results dependent on genotype of UGT2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 93(7):2500-2506
122. Simoes S et al (2005) 5-Alpha reductase inhibitors detection in doping analyses. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent andvances in doping analysis (16). Sport und Buch Straub, Köln
123. Simoni RE et al (2008) Screening for HES in human urine and possible application for dextran. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (16). Sport und Buch Straub, Köln
124. Slater GJ et al (2000) Beta-hydroxy beta-methylbutyrate (HMB) supplementation does not influence the urinary testosterone: epitestosterone ratio in healthy males. J Sci Med Sport 3:79-83
125. Smith DE et al (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos 8:337-342
126. Son J et al (2006) Screening and confirmation analyses of urinary plasma volume expanders, deextran and HES, in doping control. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (14). SportVerlag Strauss, Köln, pp 423-426
127. Sook YM et al (2006) Rapid screening of plasma volume expanders using Benedict's solution. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis (14). SportVerlag Strauss, Köln, pp 427-430
128. Sorgel F et al (1985) Oral triamterene disposition. Clin Pharmacol Ther 38:306-312
129. Sottas PE et al (2008) From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int 174:166-172
130. Sottas P-E, Robinson N, Saugy M (2009) The athlete's biological passport and indirect markers of blood doping. Handbook of Experimental Pharmacology (in press)
131. Southan GJ et al (1992) Possible indices for the detection of the administration of dihydrotestos-terone to athletes. J Steroid Biochem Mol Biol 42:87-94
132. Starka L (2003) Epitestosterone. J Steroid Biochem Mol Biol 87:27-34
133. Stopforth A et al (2007) Quantification of testosterone and epitestosterone in human urine samples by stir bar sorptive extraction - thermal desorption - gas chromatography/mass spectrometry: application to HIV-positive urine samples. J Sep Sci 30:257-265
134. Thevis M et al (2000a) Detection of the plasma volume expander hydroxyethyl starch in human urine. J Chromatogr B Biomed Sci Appl 744:345-350
135. Thevis M et al (2000b) Mass spectrometry of partially methylated alditol acetates derived from hydroxyethyl starch. J Mass Spectrom 35:77-84
136. Thevis M et al (2002) Mass spectrometric behavior of thiazide-based diuretics after electrospray ionization and collision-induced dissociation. Anal Chem 74:3802-3808
137. Thevis M et al (2007a) Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. Ther Drug Monit 29:236-247
138. Thevis M et al (2007b) Detection of manipulation in doping control urine sample collection: a multidisciplinary approach to determine identical urine samples. Anal Bioanal Chem 388:1539-1543
139. Thieme D et al (2001) Screening, confirmation and quantification of diuretics in urine for doping control analysis by high-performance liquid chromatography-atmospheric pressure ionisation tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 757:49-57
140. Thörngren J et al (2007) A new approach for screening, verifying and confirmation of prohibited doping substances. In: Schaenzer W, Geyer H, Gotzmann A, Mareck-Engelke U (eds) Recent advances in doping analysis. Sportverlag Strauss, Köln, pp 245-252
141. Tindall DJ, Rittmaster RS (2008) The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 179:1235-1242
142. Tiwari A (2007) Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia. Expert Opin Invest Drugs 16:1425-1439
143. Tsai FY et al (1991) Analysis of diuretic doping agents by HPLC screening and GC-MSD confirmation. J Pharm Biomed Anal 9:1069-1076
144. Ventura R (1994) Development of analytical methods to detect the administration of forbidden substances in sport: diuretics, probenecid and mesocarb. PhD Thesis
145. Ventura R, Segura J (1996) Detection of diuretic agents in doping control. J Chromatogr B Biomed Appl 687:127-144
146. Ventura R et al (1991) Approach to the analysis of diuretics and masking agents by high-performance liquid chromatography-mass spectrometry in doping control. J Chromatogr 562:723-736
147. Ventura R et al (1993) Fast screening method for diuretics, probenecid and other compounds of doping interest. J Chromatogr A 655:233-242
148. Ventura R et al (2008) High-throughput and sensitive screening by ultra-performance liquid chromatography tandem mass spectrometry of diuretics and other doping agents. Eur J Mass Spectrom 14:191-200
149. Vercueil A et al (2005) Physiology, pharmacology, and rationale for colloid administration for the maintenance of effective hemodynamic stability in critically ill patients. Transfus Med Rev 19:93-109
150. Waitzinger J et al (2003) Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 4:149-157
151. Welling PG (1986) Pharmacokinetics of the thiazide diuretics. Biopharm Drug Dispos 7:501-535
152. Williams RL et al (1987) Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. Pharm Res 4:348-352
153. Wilson H, Lipsett MB (1966) Metabolism of epitestosterone in man. J Clin Endocrinol Metab 26:902-914
154. World Anti-Doping Agency (WADA) (2007) The 2008 prohibited list
155. Hansch C and Leo (2008) A partition coefficient data bank, MEDCHEM Project. Pomonba College, Claremont, CA